ARTICLE | BGBx & Hayden Why Market Access Just Became Oncology Marketing's Biggest Anxiety Authors: David MacDougall, Managing Director and Co-Founder, Hayden Consulting Group Jamie Sidore, Managing Director and...
Read More
INFOGRAPHIC | BGBx Obesity Brand Insights The obesity market is moving fast. Is your strategy keeping pace? Watch the Full Recording Now
Read More
REPORT | Consulting Why Are Drug Manufacturers Cutting List Prices? Inside the 2026 WAC Reduction Trend In January 2026, seven brand-name drugs without generic competition took Wholesale Acquisition...
Read More
REPORT | Consulting The Complete Guide to Direct to Patient (DTP) Drug Programs: Strategy, Economics, and Affordability Integration Direct to Patient (DTP) programs are transforming how drug manufacturers...
Read More
REPORT | Consulting ACE-ing Launch Success Unlocking the true drivers of patient access, experience, and conversion Successful drug launches hinge on whether patients can actually access and start...
Read More
REPORT | AI 5 Ways AI is Actually Impacting Pharma Launches Download PDF Explore Our Insights
Read More
BLOG | Consulting | AI and Innovation Strategy Blood Biomarkers in Alzheimer's Disease
Read More
BLOG | Consulting | Market Access Blood Biomarkers in Alzheimer's Disease
Read More
BLOG | Consulting | Innovation & Intelligence Why AI Isn't Solving Go-to-Market Failure in Pharma — and What Actually Will Explore Our Insights
Read More
BLOG | Consulting | Market Access 2026 Oncology Market Access Trends The oncology access landscape is increasingly shaped by a dynamic “tug of war” between payer-driven cost controls...
Read More